SUPPLEMENTARY DATA

Supplementary Table 1. *Percentage of responder or non-responder mice showing 0, 1, 2 or 3 cytokines with an individual value below the average value (among the 3 pro-inflammatory cytokines IFN?, TNF and IL1?)*.

The average values for each cytokine were calculated with all responder and non-responder mice: IFN?= 203pg/ml; TNF=137pg/ml; IL1? =177pg/ml.

78.3% of responder mice show at least 2 or 3 pro-inflammatory cytokines with an individual value below the average value as compared to only 14.3% for non-responder mice.

Number of cytokines with an individual value below the average value among 3 pro-inflammatory cytokines (IFNγ, TNF or IL1β)	Responder mice after combination therapy (protected)		Non-responder mice after combination therapy (sick)	
0 among 3	4.3%		57%	
1 among 3	17.4%		28.7%	
2 among 3	78.3%	30.4%	14.3%	14.3%
3 among 3		47.9%		0%

SUPPLEMENTARY DATA

Supplementary Figure 1. *Experimental in silico approach and analytes used to identify type 0 and type 2 biomarkers*. Abs, antibodies; Diabet., Diabetogenic; Th, helper T cells; Ins., insulin; Tregs, regulatory T cells; PLN, pancreatic lymph nodes; DCs. Dendritic cells; IL, interleukin; TGF, transforming growth factor; DFA, discriminant function analysis.

1) Conditions employed for in silico experiment:

- Anti-CD3/oral insulin combination therapy
  - 10μg anti-CD3 intravenous every day for 3 days
  - 1mg oral insulin twice a week for 5 consecutive weeks
  - administered when the blood glucose value reaches 250mg/dl

2) Measurements were taken of the following analytes at various time points:

1. Blood glucose
2. Blood insulin
3. Blood auto-Abs.
4. Diabet.Th T cells
5. Diabet.Th T cells
6. Naïve Ins. specific $CD4^+$ T cells
7. Diabet. $CD8^+$ T cells
8. Naïve Ins. specific $CD8^+$ T cells
9. Diabet. regulatory T cells
10. Resting Ins. specific regulatory T cells
11. Active diabet. B cells
12. Ratio of diabet. $CD8^+$ T cells : T regs
13. Ratio of diabet. Th T cells : T regs
14. Percentage change in lymphocyte numbers
15. TNFα (islet and PLN)
16. IFNγ (islet and PLN)
17. IL-1 (islet and PLN)
18. IL-12 (islet and PLN)
19. IL-10 (islet and PLN)
20. TGFβ (islet and PLN)
21. Inflammatory DCs
22. Suppressor DCs
23. Ratio of proinflammtory:regulatory cytokines

3) DFA was used to analyze the data to identify type 0 and type 2 biomarkers at:

- 9, 10 and 11weeks of age for type 0 biomarkers
- 0 and 3 days, and 1, 2, 4 and 6 weeks after therapy for type 2 biomarkers